European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for Alzheimer’s disease, providing a response after a meeting next month.

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the March 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

Commissions do not affect our editors' opinions or evaluations. With unlimited 2% cash back on purchases, the Capital One Spark Cash Plus (rates & fees) is an excellent business cash-back card for ...

Credit: Bloomberg via Getty Images. Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that the bid “significantly undervalues” the ...

Versant Ventures has made its fourth investment in an obesity startup in eight months, co-leading a $65 million Series A round in Helicore Biopharma, a developer of an antibody drug that blocks a gut ...

Sage Ther­a­peu­tics knows it needs to do some­thing. But it doesn’t want to sell to its part­ner Bio­gen.

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Ei­sai and Bio­gen scored an ap­proval for once-month­ly IV main­te­nance dos­ing of their Alzheimer’s drug Leqem­bi, as part of what they’ve said is an on­go­ing … ...

(Reuters) -Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve ...